CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...
Medscape

CAR T Cells Produce 10-Year Remissions in Some Patients With Lymphoma

Approximately 30%-50% of patients with relapsed or refractory B-cell non-Hodgkin lymphomas have achieved durable remissions with CAR T-cell therapies targeting CD19 over follow-up periods of up to 5 ...
MedPage Today on MSN

Long-Term CAR-T Results in Lymphoma Confirm Early Promise

Lymphoma-free survival exceeding 5 years in early recipients of the cellular therapy ...
The American Journal of Managed Care

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...